drugset / Trial / NCT04567784

Neuroimaging and CBD for Opioid Use Disorder

NCT04567784 ↗

Phase 2 Completed 66 enrolled Yasmin Hurd GW Research Ltd · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The investigators propose an imaging study to investigate the neurobiological effects of CBD (vs placebo) in participants with opioid use disorder who are maintained on methadone. The purpose of the study is to determine the neural circuits and transmitters associated with the effects of CBD on to reduce craving and anxiety. The neuroimaging will be conducted in participants immediately following their first administration of CBD (800mg or placebo) and one week after the last administration (3 daily doses). This CBD administration protocol was shown in previous studies by the investigators to reduce craving and anxiety in abstinent heroin users.

Timeline

Start
2020-11-12
Primary completion
2025-06-18
Completion
2025-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 800 mg Oral